Waters P, Fadda G, Woodhall M, et al. - In an inception cohort of prospectively monitored children with acquired demyelination, researchers described serial anti-myelin oligodendrocyte glycoprotein (MOG) antibody serologies and clinical and imaging features at presentation and during follow-up. Participants in the study were 274 children with acquired demyelinating syndrome. According to this prospective cohort study, anti-MOG antibodies were observed in approximately 30% of children at presentation. Candidates were hired from July 2004 to February 2017 through the multicenter Canadian Pediatric Demyelinating Disease Study. In children with acquired demyelinating syndrome, MOG antibodies are common and are transient in approximatively half of cases. Most anti-MOG antibody–positive children experience a monophasic disease even when persistently positive. The existence of anti-MOG antibodies should not prompt the initiation of long-term immunomodulatory treatment instantly at the moment of incident demyelination.